Class Action Lawsuit Filed Against ADMA Biologics Over Alleged Securities Fraud
A class action lawsuit has been filed against ADMA Biologics (NASDAQ: ADMA) over alleged securities fraud, citing a report that accused the company of inflating revenue growth through channel stuffing. The stock dropped significantly following the allegations.
Tickers: $ADMA